[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569185":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":49,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic Test: Single Group Assignment",null,"Each subject receive a single intravenous injection of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 , and undergo PET\u002FCT imaging within the specificed time.",[13],"Diagnostic Test: 68Ga\u002F18F-TATE\u002FJR11\u002FLM3",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","68Ga\u002F18F-TATE\u002FJR11\u002FLM3","Each subject receive a single intravenous injection of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3, and undergo PET\u002FCT imaging within the specificed time.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Shaobo Yao, PhD","+8615122570279","yaoshaobo008@163.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China",{"type":39,"coordinates":40},"Point",[41,42],117.17667,39.14222,{"lat":42,"lon":41},[45],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":47,"investigatorFullName":27,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Prof.",[50],{"name":32,"class":6},"100569185",false,"NCT06690957","Somatostatin Receptor PET\u002FCT in SSTR-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":61,"type":62},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.",[67,68,69,70],"SSTR-related Disease","Tumor","Positron Emission Tomography","Metastasis",[72,73,74,75],"PET\u002FCT","SSTR","Angonist","Antagonist","2025-02-07",{"date":78,"type":79},"2025-02-11","ACTUAL",{"date":81,"type":79},"2019-02-01",{"date":83,"type":62},"2027-10-01",{"name":5,"class":6},1]